Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer-Reference-Cited by-同舟云学术

Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer

Published:2016-09 Issue: Volume:65 Page:11-20
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Hamada Tsuyoshi,Nakai Yousuke,Isayama Hiroyuki,Yasunaga Hideo,Matsui Hiroki,Takahara Naminatsu,Mizuno Suguru,Kogure Hirofumi,Matsubara Saburo,Yamamoto Natsuyo,Tada Minoru,Koike Kazuhiko

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference80 articles.

1. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study;Ueno;J Clin Oncol,2013

2. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial;Gourgou-Bourgade;J Clin Oncol,2013

3. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial;Mukherjee;Lancet Oncol,2013

4. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials);Bonnetain;Eur J Cancer,2014

5. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer;Buyse;Lancet,2000

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel approach to the analysis of Overall Survival (OS) as response with Progression-Free Interval (PFI) as condition based on the RNA-seq expression data in The Cancer Genome Atlas (TCGA);BMC Bioinformatics;2024-09-13

2. Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic cancer;Journal of Cancer Research and Clinical Oncology;2024-01-26

3. Association Between Intermediate End Points, Progression-free Survival, and Overall Survival in First-line Advanced or Recurrent Endometrial Cancer;Clinical Therapeutics;2023-10

4. Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials;Frontiers in Pharmacology;2023-06-20

5. Copula graphic estimation of the survival function with dependent censoring and its application to analysis of pancreatic cancer clinical trial;Statistical Methods in Medical Research;2023-03-15